A. Frolov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
A. Frolov has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- April Ewton
Houston Methodist Hospital, Houston, Texas, US
1 shared publication - Gustavo Rivero
Georgetown University School of Medicine
1 shared publication - J. Snijder
Baylor St Luke Medical Center, Section of Hematology/Oncology, 1 Baylor Plaza, Houston, TX, 77030, USA
1 shared publication - N. Mihyawi
Baylor St Luke Medical Center, Section of Hematology/Oncology, 1 Baylor Plaza, Houston, TX, 77030, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-7
Spontaneous remission in diffuse large cell lymphoma: a case report
Spontaneous remission in solid malignancies has been documented. However, spontaneous remission in aggressive diffuse large b cell lymphoma is exceedingly rare. Previous reports of lymphoma remission suggest that not yet fully characterized tumor-intrinsic and microenvironment mechanisms cooperate with spontaneous regression. Here, we report the case of an 88-year-old white woman with diffuse large b cell lymphoma (follicular lymphoma transformed) who achieved morphologic spontaneous remission 3 months after her diagnostic core biopsy. We examined 16 similar cases of diffuse large b cell lymphoma suggesting that spontaneous remission is preferentially observed in elderly patients soon after their biopsy microtrauma, especially if malignancies are Epstein–Barr virus driven and activated B-cell type. Our case and reported analysis highlight that anti-tumor adaptive T cell responses are potentially augmented in a subset of patients leading to lymphoma regression. In these patients, it is possible that “primed” innate anti-tumor T cell immunity is enhanced in immunogenic lymphoma subtypes after tissue biopsy. Our case and analysis not only reinforce the role of innate T cell anticancer immunity, but also originates potential proof of concept for investigation of unexplored pathways that could favorably impact T cell therapy.
- 1 February 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-7
Open AccessSpontaneous remission in diffuse large cell lymphoma: a case report
Spontaneous remission in solid malignancies has been documented. However, spontaneous remission in aggressive diffuse large b cell lymphoma is exceedingly rare. Previous reports of lymphoma remission suggest that not yet fully characterized tumor-intrinsic and microenvironment mechanisms cooperate with spontaneous regression. Here, we report the case of an 88-year-old white woman with diffuse large b cell lymphoma (follicular lymphoma transformed) who achieved morphologic spontaneous remission 3 months after her diagnostic core biopsy. We examined 16 similar cases of diffuse large b cell lymphoma suggesting that spontaneous remission is preferentially observed in elderly patients soon after their biopsy microtrauma, especially if malignancies are Epstein–Barr virus driven and activated B-cell type. Our case and reported analysis highlight that anti-tumor adaptive T cell responses are potentially augmented in a subset of patients leading to lymphoma regression. In these patients, it is possible that “primed” innate anti-tumor T cell immunity is enhanced in immunogenic lymphoma subtypes after tissue biopsy. Our case and analysis not only reinforce the role of innate T cell anticancer immunity, but also originates potential proof of concept for investigation of unexplored pathways that could favorably impact T cell therapy.